05.18.26 -- Why Dilution Gets Tricky: The Role Of Measurement Variability

Explore the crucial role of NK cells in the immune system and learn efficient methodologies for manufacturing gene-engineered NK cells and scaling up production.

Technology transfer, the transmission of bioprocess knowledge, skills, and technology, is a crucial mechanism for ensuring adequate and timely access to innovative medicines.

Customizing cell culture media is an important part of the early stages of development considering its composition is crucial for cellular therapeutics' success

Discover how our optimized CHO K1 cell lines achieved up to an 80% increase in titer while maintaining product quality through molecule-specific process development strategies.

AAV vectors hold promise for gene therapy, but removing product-related impurities remains a challenge. Learn how cell line development and process optimization are advancing rAAV production.

Demand for EVs is rising due to their therapeutic promise. Examine two scalable platforms that address production challenges to support EVs' expanding clinical and commercial applications.

Middlesex County, NJ, is a premier life sciences hub, attracting major biopharma leaders, entrepreneurs, and investors to accelerate global medical innovation.

Next-gen CLD utilizes transposase-mediated integration for speed and stability and employs an engineered cell line to enhance ADCC and a high-throughput assay for early glycosylation control.

Find out how engineered exosomes, displaying tumor-homing peptides, offer a promising tool for targeted cytotoxic drug delivery, produced efficiently with a bioreactor for critical research.

Low AAV productivity and lack of platform processes continue to be challenges, driving AAV production costs up. Uncover a robust and scalable suspension manufacturing platform for AAV production.

By increasing recombinant AAV titers, this AAV enhancer can help reduce upstream manufacturing costs and lower the cost per therapeutic dose.

See how chemically defined media and optimized bioreactor protocols increase exosome yields 40-fold while reducing commercial manufacturing costs from $10,000 to under $1,000 per dose.